Evidence map›Paper›PMID 31440769›Full record

ReviewDer Nervenarzt2019

[Prevention of cognitive decline and dementia by treatment of risk factors].

Claus Escher, Frank Jessen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Nervenarzt, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Claus EscherKlinik für Psychiatrie und Psychotherapie, Uniklinik Köln, Medizinische Fakultät, Kerpener Straße 62, 50937, Köln, Deutschland. claus.escher@uk-koeln.de.
Frank JessenKlinik für Psychiatrie und Psychotherapie, Uniklinik Köln, Medizinische Fakultät, Kerpener Straße 62, 50937, Köln, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Germany, approximately 1.6 million people are currently suffering from dementia. The prevalence of the disease is expected to double by 2060. To date there is no treatment that can prevent the onset of dementia. For this reason, the development of prevention strategies for cognitive decline and dementia is crucial.

objectivePresentation of studies on dementia prevention by treatment of arterial hypertension. Overview of current multidomain interventional studies on dementia prevention. MATERIAL AND

methodsNarrative review.

resultsWhereas in three previous randomized controlled trials on antihypertensive treatment a reduction of dementia risk could not be found, the recent SPRINT-MIND study demonstrated a reduced risk of mild cognitive impairment (MCI) and in the trend for dementia by intensified hypotensive treatment. Multidomain interventional studies suggest preventive effects, particularly in specific risk groups and also highlight the challenge of adherence to lifestyle modifications.

conclusionThe treatment of modifiable risk factors can have a preventive effects on cognitive decline and dementia. More research is needed to identify subgroups with the greatest likelihood of benefits.

Indexed as

Cognitive DysfunctionDementiaAntihypertensive AgentsGermanyHumansHypertensionRisk FactorsAntihypertensive AgentsAlzheimer’s diseaseArterial hypertensionCardiovascular eventsInterventional studiesStroke

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.